Get the Stockscreener App
1.66
5.06%
0.08
Ac Immune Sa stock is traded at $1.66, with a volume of 237.77K.
It is up +5.06% in the last 24 hours and down -21.70% over the past month.
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
See More
Previous Close:
$1.58
Open:
$1.6
24h Volume:
237.77K
Relative Volume:
1.27
Market Cap:
$148.61M
Revenue:
-
Net Income/Loss:
$-60.14M
P/E Ratio:
-2.3397
EPS:
-0.7095
Net Cash Flow:
$-68.17M
1W Performance:
+12.16%
1M Performance:
-21.70%
6M Performance:
-44.67%
1Y Performance:
-29.96%
1-Day Range:
$1.58
$1.6794
1-Week Range:
$1.45
$1.6794
52-Week Range:
$1.4299
$4.9782
Ac Immune Sa Stock (ACIU) Company Profile
Compare ACIU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
1.66 | 148.61M | 0 | -60.14M | -68.17M | -0.7095 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.47 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
599.76 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
600.51 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.61 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
256.16 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-31-24 | Initiated | BTIG Research | Buy |
| Feb-01-19 | Downgrade | UBS | Buy → Neutral |
| Jan-04-19 | Initiated | UBS | Buy |
| Apr-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-23-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-18-16 | Initiated | Credit Suisse | Outperform |
| Oct-18-16 | Initiated | Jefferies | Buy |
| Oct-18-16 | Initiated | Leerink Partners | Outperform |
View All
Ac Immune Sa Stock (ACIU) Latest News
Wells Fargo & Company MN Lowers Stock Holdings in AC Immune SA (NASDAQ:ACIU) - Defense World
Q2 Earnings Estimate for AC Immune Issued By Leerink Partnrs - Defense World
Q1 Earnings Estimate for AC Immune Issued By Leerink Partnrs - Defense World
AC Immune unveils first-in-class Morphomer targeting pathological α-synuclein - BioWorld MedTech
HC Wainwright Reiterates “Buy” Rating for AC Immune (NASDAQ:ACIU) - Defense World
AC Immune SA: Promising Phase 2 Results and Positive Outlook Drive Buy Rating - TipRanks
AC Immune reports interim outcomes from trial of Parkinson’s therapy - Yahoo Finance
AC Immune (ACIU) Shares Surge on Promising Parkinson's Trial Res - GuruFocus
AC Immune reports Phase II trial of ACI-7104.056 - The Pharma Letter
AC Immune’s Strategic Advances and Financial Highlights - TipRanks
AC Immune Announces Positive Interim Data From Early Parkinson's Disease Study - Nasdaq
AC Immune stock gains on Parkinson’s data (ACIU:NASDAQ) - Seeking Alpha
AC Immune announces additional data from Phase 2 study of VacSYn clinical trial - TipRanks
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease - The Manila Times
AC Immune SAACI-7104.056 Is Well Tolerated With No Safety Issues Reported To Date - MarketScreener
AC Immune Reports Further Positive Interim Results from - GlobeNewswire
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease - Yahoo
Benign Growth For AC Immune SA (NASDAQ:ACIU) Underpins Stock's 26% Plummet - simplywall.st
Short Interest in AC Immune SA (NASDAQ:ACIU) Rises By 23.9% - Defense World
AC Immune To Showcase Innovations In Active Immunotherapies - Evrim Ağacı
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 - GlobeNewswire
AC Immune SA to Highlight Advanced Immunotherapy Pipeline at AD/PD™ 2025 Conference - Nasdaq
ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold? - Zacks Investment Research
Promising Developments in AC Immune SA’s ACI-7104 Program Drive Buy Rating - TipRanks
AC Immune: Promising Pipeline and Financial Stability Drive Buy Rating - TipRanks
AC Immune (NASDAQ:ACIU) investors are sitting on a loss of 52% if they invested five years ago - Yahoo Finance
AC Immune (NASDAQ:ACIU) Earns “Buy” Rating from HC Wainwright - Defense World
AC Immune SA reports results for the quarter ended December 31Earnings Summary - TradingView
AC Immune SA Reports 2024 Financial Results and Strategic Advances - TipRanks
AC Immune reports FY24 EPS (51c), consensus (54c) - TipRanks
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update - The Manila Times
AC Immune SA Reports 2024 Financial Results and Announces Takeda Partnership for ACI-24.060 - Nasdaq
AC Immune Lands Massive $2.1B Potential Deal with Takeda, Extends Cash Runway to 2027 - StockTitan
AC Immune (ACIU) Projected to Post Quarterly Earnings on Thursday - Defense World
New Strong Buy Stocks for March 5th - Nasdaq
AC Immune to Participate in Upcoming Investor Conferences - GlobeNewswire
AC Immune Management Team Opens Door to Investors at Two Major Healthcare Conferences - StockTitan
AC Immune: Leader In Dementia Therapies, A Space Littered With Failures (ACIU) - Seeking Alpha
Contrasting Silence Therapeutics (NASDAQ:SLN) & AC Immune (NASDAQ:ACIU) - Defense World
Alzheimer's Disease Clinical Trial Pipeline | 110+ Companies Pioneering Breakthroughs in Treatment | - EIN News
AltPep Corporation Appoints Alan Colowick, M.D., M.P.H. To Its Board - citybiz
Down -9.7% in 4 Weeks, Here's Why You Should You Buy the Dip in AC Immune (ACIU) - Yahoo Finance
AltPep Corporation Appoints Alan Colowick, M.D., M.P.H. to Board of Directors - Business Wire
Leerink Partnrs Predicts Increased Earnings for AC Immune - MarketBeat
3 US Penny Stocks With Market Caps Over $100M To Consider - Simply Wall St
Leerink Partnrs Increases Earnings Estimates for AC Immune - Defense World
New Strong Buy Stocks for January 31st - Yahoo Finance
Updates in Therapeutic Development: Clinical Trial Readouts to Watch in the First Half of 2025 - Neurology Live
Five promising small-cap pharmaceutical companies taking on Alzheimer’s - Kursiv Media
Ac Immune Sa Stock (ACIU) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.04%
2.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):